(Q38765037)

6 September 2017

1 reference

title

Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections (English)

1 reference

6 September 2017

0 references

1 reference

A S Bayer

1

1 reference

PubMed ID

2695331

6 September 2017

language of work or name

1 reference

1 December 1989

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

6 September 2017

1 reference

6 September 2017

8

1 reference

6 September 2017

12

1 reference

6 September 2017

1102-1110

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01975177

6 September 2017

0 references

cites work

Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Efficacy of ciprofloxacin in experimental arthritis caused by Escherichia coli--in vitro-in vivo correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Ciprofloxacin concentrations in bone and muscle after oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

The diffusion of pefloxacin into bone and the treatment of osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Penetration of enoxacin into bronchial secretions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Pharmacokinetics of ciprofloxacin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Ciprofloxacin in the treatment of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

Mechanisms of aminoglycoside resistance in variants of Pseudomonas aeruginosa isolated during treatment of experimental endocarditis in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975177

In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents

21 January 2018

1 reference

12 December 2020

Acute arthritis caused by gram-negative bacilli: a clinical characterization

1 reference

12 December 2020

Experimental E. coli arthritis in the rabbit. A model of infectious and post-infectious inflammatory synovitis

1 reference

12 December 2020

Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits

1 reference

12 December 2020

Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs

1 reference

12 December 2020

Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis

1 reference

12 December 2020

The activity of ciprofloxacin and other 4-quinolones againstChlamydia trachomatis andMycoplasmas in vitro

1 reference

12 December 2020

Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis

1 reference

12 December 2020

Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin.

1 reference

12 December 2020

[Antituberculosis chemotherapy including ofloxacin in patients with pulmonary tuberculosis not treated previously]

1 reference

12 December 2020

Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections

1 reference

12 December 2020

Uptake of ciprofloxacin by human neutrophils

1 reference

12 December 2020

Ciprofloxacin therapy in cystic fibrosis

1 reference

12 December 2020

Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa

1 reference

12 December 2020

Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis

1 reference

12 December 2020

Ciprofloxacin: comparative data in cystic fibrosis

1 reference

12 December 2020

Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis

1 reference

12 December 2020

Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis

1 reference

12 December 2020

Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis

1 reference

12 December 2020

Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

1 reference

12 December 2020

Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli

1 reference

12 December 2020

[Therapeutic effect of ofloxacin (DL 8280) on pulmonary tuberculosis. (Report of a one year-administration study on sixteen treatment-failure patients)]

1 reference

12 December 2020

Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis.

1 reference

12 December 2020

Cystic Fibrosis—A Challenging Long-Term Chronic Disease

1 reference

12 December 2020

The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia

1 reference

12 December 2020

In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid

1 reference

12 December 2020

Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria

1 reference

12 December 2020

Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin.

1 reference

12 December 2020

Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis.

1 reference

12 December 2020

Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01975177

1 reference

PubMed ID

2695331

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

2695331